Burkholderia mallei and B. pseudomallei are important human pathogens and cause the diseases glanders and melioidosis, respectively. Both organisms are highly infectious when inhaled and are inherently resistant to many antimicrobials, thus making it difficult to treat pneumonic Burkholderia infections. We investigated whether it was possible to achieve rapid protection against inhaled Burkholderia infection by using inhaled immunotherapy. For this purpose, cationic liposome DNA complexes (CLDC), which are potent activators of innate immunity, were used to elicit the activation of pulmonary innate immune responses. We found that mucosal CLDC administration before or shortly after bacterial challenge could generate complete or nearly complete protection from inhalational challenge with 100% lethal doses of B. mallei and B. pseudomallei. Protection was found to be dependent on the CLDC-mediated induction of gamma interferon responses in lung tissues and was partially dependent on the activation of NK cells. However, CLDC-mediated protection was not dependent on the induction of inducible nitric oxide synthase, as assessed by depletion studies. We concluded that the potent local activation of innate immune responses in the lung could be used to elicit rapid and nonspecific protection from aerosol exposure to both B. mallei and B. pseudomallei.
Pathogenic Burkholderia species, including B. mallei and B. pseudomallei, are gram-negative facultative intracellular bacteria. Burkholderia pseudomallei is a soil bacterium that causes a disease known as melioidosis, while B. mallei is an obligate mammalian pathogen that causes glanders (26, 37) . The primary host for B. mallei is equines, though the organism also can infect other mammals, including humans (21, 22) . Without antimicrobial therapy, infection with B. mallei is nearly 100% fatal (37) . Both B. mallei and B. pseudomallei are classified as category B select agents by the Centers for Disease Control and Prevention due to their high potential for use as bioweapons and their high resistance to antibiotics (1, 28, 33, 39) . Currently, prolonged (up to 6 months) antimicrobial therapy of Burkholderia infection is required (31, 40) . Currently there is no vaccine available for preventing infection with Burkholderia organisms.
Proinflammatory cytokines are critical for generating protective immunity to acute Burkholderia infection. For example, mice unable to produce interleukin-12 (IL-12) are highly susceptible to infection with B. mallei, and treatment with recombinant IL-12 provides partial protection against infection. (2, 29) . Tumor necrosis factor ␣ (TNF-␣) also plays an important protective role in B. pseudomallei infection, as the antibody neutralization of TNF-␣ increases susceptibility to infection, and TNF-␣ Ϫ/Ϫ and TNF-␣-receptor Ϫ/Ϫ (TNF-␣-R Ϫ/Ϫ ) mice are highly susceptible to lethal infection (4, 30) . Gamma interferon (IFN-␥) also is critical in generating protective immunity to Burkholderia infection (29, 30) . Indeed, even very low concentrations of IFN-␥ are sufficient to generate protection against B. pseudomallei infection (14) .
Given the inherent antimicrobial resistance of Burkholderia and the lack of effective vaccines, there is a need for alternative approaches to rapidly protect from aerosol infection. The nonspecific activation of innate immunity by the administration of immunotherapeutics represents one such approach. For example, it was shown previously that the systemic (intraperitoneal [i.p.]) administration of CpG oligonucleotides prior to infection provided protection against low-dose aerosol B. mallei challenge (38) . A similar CpG oligonucleotide treatment approach also was shown to be effective against systemic challenge with B. pseudomallei (41) . However, an inhaled immunotherapeutic could be more rapidly administered and generate protective immunity more rapidly than a parenterally administered agent. Therefore, we evaluated the potential effectiveness of a mucosally administered immunotherapeutic for protection from inhaled Burkholderia infection. The studies described here used cationic liposome-DNA complexes (CLDC) as immunotherapeutics, as our previous investigations have shown CLDC to be potent inducers of innate immunity (11) .
We investigated the effects of the timing of mucosal CLDC administration on the induction of protective immunity and whether CLDC immunotherapy could protect against both B. mallei and B. pseudomallei infection. These studies also used a rigorous high-dose inhalational Burkholderia challenge model and investigated immunological mechanisms of protection. We report here that the intranasal (i.n.) administration of a liposome-based immunotherapeutic was capable of eliciting significant protection from pneumonic Burkholderia infec-tion. These results suggest that this approach is an effective strategy for generating rapid and nonspecific protection from the inhalation of acutely pathogenic bacteria. inflated with formalin via tracheal injection prior to being removed and then were placed in formalin solution for 24 h. After 24 h, organs were transferred into 70% ethanol for another 7 days. Tissues then were sectioned and stained with hematoxylin and eosin. Organ pathology was assessed by an experienced veterinary pathologist (H. Bielefeldt-Ohmann).
Cytokine quantitation. To assess the effects of immunotherapy on cytokine production in the lungs, CLDC (or diluent) was administered i.n. to mice (n ϭ 4 per group), which were euthanized 6 or 24 h later. Lungs were harvested and homogenized using a Stomacher 80 Biomaster (Seward) in 4 ml sterile saline. The lung homogenate was clarified by centrifugation, and the supernatants were frozen at Ϫ80°C prior to cytokine analysis. Concentrations of IL-12p40 and IFN-␥ were measured by commercial enzyme-linked immunosorbent assays (ELISAs) according to the manufacturer's instructions (R&D Systems, Minneapolis, MN).
In vitro infection of macrophages with B. mallei. The mouse alveolar macrophage cell line (AMJ2; American Type Tissue Collection, Manassas, VA) was used to investigate the ability of CLDC supernatants to enhance bactericidal activity in vitro. Cells were cultured in 24-well plates in complete medium without antibiotics. Cells were cultured in complete medium that consisted of minimal essential medium (Invitrogen, Carlsbad, CA) containing 10% fetal bovine serum (Gemini Bio-Products, West Sacramento, CA), 2 mM L-glutamine (Invitrogen), 1ϫ nonessential amino acids (Invitrogen), and 0.075% sodium bicarbonate (EMD Science, Gibbstown, NJ). Adherent cells were infected with B. mallei at a multiplicity of infection (MOI) of 2 for 1 h in 250 l medium at 37°C and 5% CO 2 . Extracellular bacteria were removed by washing the cells three times with PBS, followed by treatment with medium plus 350 g/ml kanamycin (Sigma-Aldrich) for 1 h. After incubation with kanamycin for 1 h, the cells were washed and then cultured in complete medium with 10 g/ml kanamycin for an additional 24 h. To quantitate intracellular bacterial numbers, the cells were washed three times with PBS and then lysed with sterile double-distilled water containing 0.01% Triton X-100. Serial dilutions of lysate were plated on BB4G agar plates, and plates were incubated at 37°C for 48 h, at which time colonies were counted.
Cytokine inhibition of macrophage infection with B. mallei. The ability of cytokines elicited by CLDC immunotherapy to inhibit the intracellular replication of B. mallei in infected macrophages was assessed using AMJ2 alveolar macrophages. AMJ2 cells (1 ϫ 10 5 per well in triplicate wells of 24-well plates) were pretreated for 24 h before infection with diluted (1:10 or 1:100) supernatants from spleen cells of mice treated in vivo with CLDC or with supernatants from control spleen cells. Briefly, supernatants were generated as described previously by using overnight cultures of spleen cells prepared from mice injected intravenously (i.v.) with 200 l CLDC 3 h prior to sacrifice (11) . It was determined by ELISA that the supernatants from spleen cells of CLDC-injected mice contained 3 ng/ml IFN-␥ and 140 pg/ml TNF-␣ (data not shown).
Neutralizing antibodies were used to identify key cytokines that may have been responsible for generating antibacterial activity in supernatants from spleen cells. Thus, supernatants were treated with 10 g/ml anti-IFN-␥ antibody (clone R4.6A2) (eBioscience, San Diego, CA), 10 g/ml of anti-TNF-␣ antibody (clone TN3-19.12) (eBioscience), or a mixture of equal concentrations of both antibodies. Controls included incubating the supernatants with equivalent amounts of irrelevant isotype-matched antibodies (clones eBRG1 and eBio299Arm; eBiosciences) at 37°C for 30 min prior to the addition of supernatants to cells. Cells were incubated with supernatants for 24 h and then infected with B. mallei, and intracellular bacterial concentrations were determined as noted above. The effects of individual cytokines on inhibiting the B. mallei infection of AMJ2 cells also were evaluated. AMJ2 cells were incubated with recombinant murine IFN-␥ (10 ng/ml; Preprotec, Rocky Hill, NJ) or murine TNF-␣ (10 ng/ml; Preprotec) for 24 h prior to B. mallei infection. Twenty-four hours after infection, intracellular concentrations of bacteria were determined as indicated above.
NK cell depletion. NK cells were depleted systemically in mice (n ϭ 5 per group) by the injection of anti-asialo GM1 antibody (Wako Chemicals, Richmond, VA), as described previously (9, 11, 13) . Briefly, mice were injected i.p. with 50 g of anti-asialo GM1 antibody 24 h prior to CLDC treatment. This treatment was found to decrease the number of splenic and lung NK cells by more than 75% (data not shown). The mice then were infected i.n. with B. mallei 24 h after that (48 h after the injection of asialo-GM1 antibody). Controls included mice injected i.p. with an equivalent amount of rabbit immunoglobulin G antibody (Jackson Immunoresearch, West Grove, PA).
Inhibition of nitric oxide production in vivo. Inducible nitric oxide synthase (iNOS) activity was inhibited by the treatment of mice with aminoguanidine (AG) (Sigma-Aldrich). Mice were injected i.p twice daily with 0.2 ml of a 50-mg/ml solution of AG prepared in PBS, starting 5 days prior to infection and 1580 GOODYEAR ET AL. INFECT. IMMUN.
continuing until 7 days post infection, using a previously described protocol (5, 7) . Control mice were injected with an equal volume of sterile PBS. Statistical analysis. Statistical analysis was performed using Prism 5.0 software (GraphPad, La Jolla, CA). For the comparison of two groups, two-tailed t tests were performed. For the comparison of more than two groups, one-way analysis of variance (ANOVA) was done, followed by Tukey's multiple means comparison test. Survival times were compared using Kaplan-Meier curves and the log-rank test. Data were considered statistically significant for P Ͻ 0.05.
RESULTS
Mucosal administration of CLCD immunotherapy protects mice from acute B. mallei pneumonic infection. Previous studies demonstrated that systemic immunotherapy using CpG oligonucleotides could provide protection from chronic infection following low-dose B. mallei pneumonia (38) . However, we wished to determine whether mucosal immunotherapy with a liposome-based immunotherapeutic was effective in an acutely lethal B. mallei pneumonia model. Therefore, we conducted protection studies in mice challenged with a high dose (10ϫ LD 50 ) of B. mallei by the i.n. route.
In the first studies, we assessed the effects of the timing of CLDC administration on the induction of protective immunity. BALB/c mice (n ϭ 5 per group) were administered 20 l of CLDC by the i.n. route, either 24 h prior to infection, concurrently with infection, or 24 h after infection. Mice then were infected i.n. with 10ϫ LD 50 (approximately 1 ϫ 10 4 CFU) of B. mallei and monitored for effects on survival. We observed that the administration of CLDC 24 h prior to infection generated complete protection from lethal B. mallei infection (Fig. 1) . Concurrent i.n. administration of CLDC immunotherapy provided partial protection from lethal infection, whereas treatment 24 h after infection did not generate significant protection ( Fig. 1 ). In addition, the administration of CLDC 6 h after infection also failed to elicit significant protection (data not shown). We also noted that protection elicited by mucosal CLDC immunotherapy prevented lethal acute infection but failed to completely protect from chronic infection, as approximately 50% of treated mice developed chronic infection by day 60 after challenge (data not shown). Thus, pretreatment by the i.n. administration of liposome-based immunotherapy was sufficient to generate significant protection from high-dose inhalational challenge with B. mallei.
Experiments then were conducted to assess the dose responsiveness of CLDC protection from B. mallei challenge by using the 24 h of pretreatment model. Mice (n ϭ 5 per group) were pretreated with the standard concentration of CLDC or with CLDC diluted 1:2 or 1:20 in diluent (Fig. 1) . We found that the administration of CLDC diluted 1:2 still provided significant (P Ͻ 0.01) protection, whereas CLDC diluted 1:20 failed to elicit protection.
We next assessed the ability of CLDC immunotherapy to protect from a higher B. mallei challenge dose. Mice were subjected to challenge with 50ϫ LD 50 (5 ϫ 10 4 CFU), and the effects on survival time were assessed. We found that CLDC immunotherapy still provided significant protection in this higher-dose challenge model. Though 80% of the mice succumbed to this high-dose challenge, the median survival time for CLDC-treated mice was 4 days, whereas it was 2 days for untreated mice (P ϭ 0.003) (data not shown). We also assessed whether increasing the CLDC dose increased protection. Increasing the dose of CLDC administered by doubling the concentration of liposomes and plasmid DNA (and still administering the same i.n. volume of CLDC) did not, however, increase survival significantly over that elicited by the administration of the standard amount of CLDC (data not shown).
Burkholderia mallei and B. pseudomallei are related pathogens, but they also possess some key differences with respect to genomic complexity and the numbers of potential virulence factors (17, 25) . Therefore, we conducted challenge studies with B. pseudomallei to determine whether CLDC immunotherapy also was capable of eliciting protective immunity against pneumonic infection with this organism. BALB/c mice (n ϭ 5 per group) were treated with CLDC i.n. 24 h prior to infection and then were subject to i.n. infection with 10ϫ LD 50 (1 ϫ 10 4 CFU) of B. pseudomallei, and the effects on survival times were assessed (Fig. 1) . We found that CLDC immunotherapy was effective in completely protecting mice from lethal pneumonic infection with B. pseudomallei. Thus, CLDC immunotherapy was capable of eliciting broadly protective immunity against two species of Burkholderia.
Reduced bacterial burden and organ pathology in mice treated with CLDC immunotherapy. The preceding studies demonstrated that CLDC immunotherapy could protect against lethal respiratory Burkholderia infection in a dose-dependent fashion. Therefore, studies were conducted next to elucidate the mechanisms of protection. First, the effects of CLDC treatment on bacterial burdens in the lungs, spleen, and liver were assessed. BALB/c mice (n ϭ 5 per group) were sham treated or were treated with CLDC i.n. 24 h prior to infection and then were subjected to infection with approximately 1 ϫ 10 4 CFU B. mallei i.n. The mice were euthanized 3 days after infection and bacterial were burdens determined, as described in Materials and Methods. We found that there were significant (P Ͻ 0.0001) reductions in the bacterial burdens in lung, liver, and spleen in CLDC-treated mice compared to that in untreated mice (Fig. 2) .
CLDC immunotherapy did not, however, generate complete sterilizing immunity. For example, nearly all CLDC-treated mice, though they survived acute infection, eventually developed chronic disseminated B. mallei infection in the liver and spleen. Bacterial burdens in the lung remained below the limit of detection (50 CFU) on day 21, 30, 45, or 60 after infection. However, increasing bacterial burdens were noted in the liver and especially the spleen at later time points following CLDC treatment and B. mallei challenge (data not shown).
Pretreatment with CLDC immunotherapy also substantially reduced acute organ pathology in B. mallei-infected mice. In untreated mice (n ϭ 4 per group) euthanized 3 days after B. mallei challenge, there was marked neutrophil infiltration in the lungs, along with hemorrhage from pulmonary vessels, the necrosis of respiratory epithelium, and the apoptosis of leukocytes and lung parenchyma (Fig. 3) . In contrast, in CLDCtreated mice the lung neutrophil infiltrate was reduced and hemorrhage was not observed in pulmonary vessels.
In untreated B. mallei-infected mice, hepatic lesions consisted of infiltrates of neutrophils and monocytes. In the livers of untreated mice there were large areas of necrosis, and in some mice hepatic lesions coalesced, whereas hepatic lesions in CLDC treated mice showed no evidence of necrosis and generally were much smaller (Fig. 3) . Important changes in used an in vitro infection system consisting of AMJ2 cells (an alveolar macrophage line) and supernatants from spleens of mice that had been injected i.v. with CLDC. In a previous study, we found that spleen cells were a major source of cytokine production in CLDC-treated mice (11) . AMJ2 cells were treated with CLDC supernatants (or supernatants from untreated control mice) for 24 h. The cells then were infected with B. mallei at an MOI of 2, and 24 h later the numbers of intracellular bacteria were determined. The preincubation of macrophages with supernatants from CLDC-treated mice, but not supernatants from untreated control mice, resulted in significant reduction in the numbers of viable intracellular B. mallei (Fig. 4) . We also observed the inhibition of B. mallei infection in macrophage cultures with supernatants from CLDC-stimulated lungs, but the effect was much less potent than that with spleen supernatants (data not shown). Significant antibacterial activity was observed when supernatants were diluted 1:1 (not shown) or 1:10, but it was lost when supernatants were diluted 1:100. In previous studies, CLDC were shown to elicit large amounts of IFN-␥ and smaller amounts of TNF-␣, both of which have antibacterial activity against Burkholderia (4, 29, 30) . Therefore, we used neutralization experiments to assess the relative contribution of each cytokine to antibacterial activity. The neutralization of IFN-␥ activity resulted in the significant abrogation of the macrophage antibacterial activity of CLDC supernatants (Fig.  4) . In contrast, the neutralization of TNF-␣ activity had a much smaller effect. However, the neutralization of both cytokines resulted in the greater inhibition of antibacterial activity, suggesting that TNF-␣ production contributed to the effectiveness of IFN-␥ in suppressing B. mallei replication in infected macrophages. Finally, the pretreatment of AMJ2 cells with 10, 1, or 0.1 ng/ml recombinant IFN-␥ resulted in 100, 98, and 98% inhibition of bacterial growth, respectively (data not shown). These results indicated that the CLDC-induced production of IFN-␥ mediated many of the protective effects of CLDC immunotherapy noted in vivo, particularly since we have observed that alveolar macrophages are one of the primary early target cells for Burkholderia infection in the lungs (data not shown). i.n. administration of CLDC elicits production of IL-12 and IFN-␥ in the lungs. Both IL-12 and IFN-␥ are known to play critical roles in protective immunity to Burkholderia infection (2, 18-20, 29, 30) . In addition, the preceding in vitro studies indicated that IFN-␥ could control Burkholderia replication in alveolar macrophages, a likely target cell for the inhalational route of infection. Therefore, we assessed the ability of the inhalational delivery of CLDC to elicit IL-12 and IFN-␥ production in the lungs. Six and 24 h after the i.n. administration of CLDC, IL-12 and IFN-␥ concentrations in lung tissues were determined by ELISA (Fig. 5 ). Significant increases in the concentrations of both IL-12 and IFN-␥ were observed in lung tissues 24 h following the i.n. delivery of CLDC, with smaller increases noted at 6 h after administration. These results indicated that the inhalational delivery of relatively low doses of CLDC to the lung could trigger the significant production of a key cytokine (IFN-␥) responsible for suppressing the intracellular replication of B. mallei. The kinetics of cytokine induction in the lung in response to CLDC immunotherapy also may explain why pretreatment with CLDC 24 h before challenge did elicit protective immunity, whereas treatment 6 h after challenge did not. 
IFN-␥ is necessary for CLDC-mediated protection in vivo.
Experiments next were conducted to directly elucidate the in vivo role of IFN-␥ in CLDC-mediated protection from lethal challenge with B. mallei. For these experiments, we used IFN-␥ Ϫ/Ϫ mice on the BALB/c background. In addition, a much lower challenge dose of B. mallei was administered (0.5 LD 50 or 500 CFU), since IFN-␥ Ϫ/Ϫ mice are known to be exquisitely sensitive to Burkholderia infection (29, 30) . Untreated IFN-␥ Ϫ/Ϫ mice, IFN-␥ Ϫ/Ϫ mice treated with CLDC 24 h prior to infection (IFN-␥ Ϫ/Ϫ plus CLDC), and wild-type BALB/c mice were infected with 0.5 LD 50 (500 CFU) of B. mallei i.n. (Fig. 6) . We observed that the CLDC pretreatment of IFN-␥ Ϫ/Ϫ mice failed to elicit protective immunity, indicating that IFN-␥ was a key component of the protective immunity elicited by CLDC immunotherapy.
The role of IFN-␥ in suppressing B. mallei replication in vivo also was assessed. Bacterial burdens in the lung, liver, and spleen of IFN-␥ Ϫ/Ϫ mice treated with CLDC were compared to those of untreated IFN-␥ Ϫ/Ϫ mice and wild-type mice on day 2 after low-dose i.n. challenge with B. mallei. As expected, the numbers of bacteria in all three organs from IFN-␥ Ϫ/Ϫ mice were significantly higher than those in organs from wildtype mice (Fig. 6) . However, significant differences were not observed when the numbers of bacteria in untreated IFN-␥ Ϫ/Ϫ mice and CLDC-treated IFN-␥ Ϫ/Ϫ mice were compared (Fig.  6) . Thus, these data are consistent with the conclusion that IFN-␥ was necessary for CLDC immunotherapy to effectively suppress B. mallei replication and to increase survival following pulmonary challenge.
Role of NK cells in CLDC-induced protection from B. mallei challenge. Previous studies have indicated that NK cells were the major source of IFN-␥ production following systemic (i.v.) treatment with CLDC (10, 34) . However, the role of NK cells in mediating CLDC-induced pulmonary immunity to bacterial challenge has not been explored previously. Prior studies have revealed that multiple cell types, including macrophages, CD8 ϩ T cells, and NK cells, produce IFN-␥ in response to Burkholderia infection (14, 29) . To elucidate the role of NK cells in CLDC protection, NK cells were depleted systemically using the asialo GM1 antibody (9, 11, 13, 16) . The antibody was administered 48 h prior to infection, and then the mice were treated 24 h prior to infection by the i.n. administration of CLDC. Mice then were infected with 10ϫ LD 50 of B. mallei and monitored for survival.
There was a significant reduction in survival (P Ͻ 0.01) of CLDC-treated mice depleted of NK cells compared to that of CLDC-treated mice not depleted of NK cells (Fig. 7) . However, CLDC-treated and NK-depleted mice still had a significant improvement in survival compared to that of untreated mice (Fig. 7) . Thus, these results indicated that NK cells were necessary for full CLDC-mediated protection. However, partial protection still was observed in NK cell-depleted mice, suggesting either that other cell types besides NK cells also contributed to the protective effects of CLDC therapy or that the residual NK cells not depleted by the administration of anti-asialo GM1 antibody were sufficient to elicit partial protection.
The role of NK cells in regulating the bacterial burden also was assessed. Bacterial burdens in the lung, liver, and spleen of mice depleted of NK cells and treated with CLDC were determined 3 days after infection. Bacterial burdens in NK celldepleted and CLDC-treated mice were significantly increased in all three organs compared to those of mice treated with CLDC immunotherapy alone (Fig. 7) . In addition, significant reductions in bacterial burdens also were observed in NK celldepleted and CLDC-treated mice compared to those of untreated mice. These results are consistent with the idea that NK cells activated by CLDC immunotherapy contribute to antibacterial activity, most likely by the secretion of IFN-␥.
Nitric oxide production is not necessary for CLDC-mediated protection. The preceding in vitro and in vivo experiments demonstrated that IFN-␥ was critical to the therapeutic effectiveness of CLDC immunotherapy. IFN-␥ also is known to be a potent inducer of NOS2 (iNOS) activity, with the subsequent production of nitric oxide (24) tion, which in turn mediates bacterial killing. Other in vitro studies have shown that Burkholderia species may downmodulate nitric oxide production in order to enhance its survival (3, 15, 23, 35, 36) . In contrast to the results obtained in these in vitro studies, in vivo B. pseudomallei challenge studies using NOS2 Ϫ/Ϫ mice have failed to demonstrate a role for nitric oxide in controlling infection (8) .
Given the critical role of IFN-␥ in mediating the protective effects of CLDC immunotherapy, we wished to determine whether the induction of iNOS activity and nitric oxide production was necessary for CLDC activity. To address this question, we used the iNOS inhibitor AG to block the production of nitric oxide in vivo. Mice were treated with AG beginning 5 days prior to infection. Mice then were treated with CLDC i.n. 24 h prior to infection and then were infected i.n. with 15ϫ LD 50 (1.5 ϫ 10 4 CFU) of B. mallei. We observed that pretreatment with AG had no effect on CLDC protection (Fig. 8) . To ensure that the AG treatment protocol we used effectively inhibited nitric oxide production, in a separate experiment we injected AG-treated mice with lipopolysaccharide and assessed nitric oxide production in serum 6 h later, and we found that AG treatment completely suppressed lipopolysaccharide-induced nitric oxide production (data not shown). Moreover, in naive mice not treated with AG, we also noted that CLDC treatment failed to induce detectable nitric oxide production in lung tissues or alveolar lavage fluid (data not shown). By realtime PCR analysis, we also failed to observe increased iNOS expression in lung tissues of mice treated with CLDC (data not shown). Thus, several lines of evidence indicated that the induction of nitric oxide production was not critical for CLDCmediated protection from pneumonic infection with B. mallei, although we cannot completely rule out a minor role for NO in protection.
DISCUSSION
The results presented here indicated that the mucosal delivery of a potent activator of innate immunity could provide significant protection from lethal pneumonic infection with both B. mallei and B. pseudomallei. The most effective protection was achieved when mice were pretreated with CLDC 24 h prior to challenge, which suggested that critical immune protective mechanisms had to be active at the time of initial contact with the inhaled bacteria to be fully effective. The local, but not systemic, induction of IFN-␥ release was required for protection, and protection appeared to be independent of nitric oxide production. Although previous studies found that the systemic administration of CpG-based immunotherapeutics could protect mice from the development of chronic pneumonia following low-dose Burkholderia challenge, these are the first studies to our knowledge to demonstrate effective protection from acutely lethal respiratory Burkholderia infection following the inhalational delivery of an immunotherapeutic (2, 41) .
IFN-␥ played a critical role in the protective effects elicited by CLDC immunotherapy. In support of this, we observed that IFN-␥ Ϫ/Ϫ mice were completely unprotected by CLDC immunotherapy. It is likely that the primary source of IFN-␥ production elicited by CLDC was from activated NK cells. The potent activation of NK cells and IFN-␥ release from the lungs has been reported previously following CLDC immunotherapy (11) . In the current study, we also demonstrated that NK cells played a role in the protective effects mediated by CLDC. However, the requirement for NK cells to mediate the protec- tive effects of CLDC was more apparent at lower challenge doses. For example, NK-depleted, CLDC-treated mice challenged with 8ϫ LD 50 (8 ϫ 10 3 CFU) had a 60 to 80% survival rate, whereas mice infected with 12ϫ LD 50 (1.2 ϫ 10 4 CFU) has only a 20% survival rate. Nevertheless, both of these challenge doses produced 100% mortality in untreated mice.
Despite a series of in vitro studies that have shown that nitric oxide is important for the bactericidal effects of IFN-␥ against both B. pseudomallei and B. mallei, in our studies we failed to find a role for nitric oxide in CLDC-mediated protective activity (3, 15, 23, 35, 36) . Our findings thus are in agreement with a previous in vivo study wherein mice lacking the iNOS gene (NOS2 Ϫ/Ϫ ) did not exhibit increased susceptibility to B. pseudomallei infection (8) . Thus, we concluded that CLDCmediated protection from lethal B. mallei pneumonia was largely independent of nitric oxide production.
Although the mucosal administration of CLDC elicited complete protection against acute B. mallei infection, the infection was not completely eliminated. For example, when mice surviving the acute challenge were monitored out to 60 days, we observed the recrudescence of infection in the spleens and livers of 80 to 90% of mice. Thus, it would be important to follow up CLDC immunotherapy with conventional antimicrobial therapy to assure the complete eradication of Burkholderia. In summary, these studies indicate that appropriately timed mucosally administered immunotherapy may induce effective nonspecific protection against pneumonic intracellular bacterial pathogens such as B. mallei and B. pseudomallei.
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